Home Contact Sitemap login Checkout

BioAlberta
  • Home
  • About
    • About
    • The BioAlberta Team
    • From The President
    • What We Do
    • Board of Directors
    • Committees
    • Industry Partners
    • Hall Of Fame
  • Boosting Biotech
  • Industry Facts
    • Industry Facts
    • Medical Technology & Devices
    • Health Biotechnology & Pharmaceuticals
    • Agricultural Biotechnology
    • Industrial Biotechnology
    • Functional Foods & Natural Health Products
    • Environmental Biotechnology
    • Industry Terms
  • Events
    • Events
    • Annual Events & Activities
    • Archived Events
      • Archived Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
      • 2017 Events
      • 2016 Events
      • 2015 Events
      • 2014 Events
  • News
    • News
    • Archived News
      • Archived News
      • 2020 News
      • 2019 News
      • 2018 News
      • 2017 news
      • 2016 News
      • 2015 News
      • 2014 News
  • Member Area
    • Member Area
    • Member Marketplace
    • Join Now
    • Member Benefits
      • Member Benefits
      • How To Access Member Benefits
    • Current Members and Life Sciences Industry
    • Current Members by Category
    • Profiled Company
      • Profiled Company
      • Previously Profiled Companies
  • Resources
    • Resources
    • Other Resources
  • Contact
Home Print This Page

EDMONTON, ALBERTA — RJH Biosciences Inc. has announced a grant from the Bill & Melinda Gates Foundation to develop a new device to enable ‘Immunotherapy On-the-Go’. RJH Biosciences Inc., a privately held biotech company in Edmonton, Alberta, will pursue a Phase I Project under the Grand Challenges Explorations initiative to develop a new mode of immunotherapy.


Recently emerging immunotherapy has excited the medical field by creating novel forms of therapy, especially for deadly cancers. Immunotherapy is now being explored in the treatment of different diseases, with hundreds of clinical immunotherapy studies underway around the world. Current immunotherapy relies on viruses to manipulate and stimulate the immune system by modifying patients’ cells outside the body. This protocol is costly ($500,000 per treatment is typical) and requires extensive facilities to undertake the therapy.  As a result, this kind of therapy is not accessible to most  patients, especially in the Developing World.


Read full press release details.

Contact Us
Suite 202
10055 - 106 Street NW
Edmonton, Alberta T5J 2Y2
Canada
Ph:  780.425.3804
Fx:  780.409.9263
admin@BioAlberta.com
Quick Links
Home
About
Industry Facts
News
Events
Member Area
Publications
Contact
Return Policy
Privacy
Terms of Use
Connect
BioAlberta: Twitter linkBioAlberta: linkedin linkBioAlberta: YouTube linkBioAlberta: facebook link